Connect Biopharma (CNTB) Competitors $0.95 0.00 (-0.36%) Closing price 06/25/2025 03:59 PM EasternExtended Trading$0.92 -0.04 (-3.71%) As of 04:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTB vs. BTMD, INBX, MNPR, SCPH, GNFT, IMAB, CRGX, FDMT, PRQR, and DRUGShould you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include biote (BTMD), Inhibrx (INBX), Monopar Therapeutics (MNPR), scPharmaceuticals (SCPH), Genfit (GNFT), I-Mab (IMAB), CARGO Therapeutics (CRGX), 4D Molecular Therapeutics (FDMT), ProQR Therapeutics (PRQR), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry. Connect Biopharma vs. Its Competitors biote Inhibrx Monopar Therapeutics scPharmaceuticals Genfit I-Mab CARGO Therapeutics 4D Molecular Therapeutics ProQR Therapeutics Bright Minds Biosciences biote (NASDAQ:BTMD) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation. Which has better valuation & earnings, BTMD or CNTB? biote has higher revenue and earnings than Connect Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratiobiote$197.19M1.15$3.16M$0.616.79Connect Biopharma$26.03M2.03-$15.63MN/AN/A Do analysts prefer BTMD or CNTB? biote presently has a consensus price target of $8.00, suggesting a potential upside of 93.24%. Connect Biopharma has a consensus price target of $7.00, suggesting a potential upside of 635.06%. Given Connect Biopharma's higher possible upside, analysts plainly believe Connect Biopharma is more favorable than biote.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score biote 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Connect Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, BTMD or CNTB? biote has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.27, meaning that its stock price is 127% less volatile than the S&P 500. Does the media favor BTMD or CNTB? In the previous week, biote and biote both had 1 articles in the media. Connect Biopharma's average media sentiment score of 1.19 beat biote's score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the news media. Company Overall Sentiment biote Neutral Connect Biopharma Positive Is BTMD or CNTB more profitable? biote has a net margin of 10.93% compared to Connect Biopharma's net margin of 0.00%. Connect Biopharma's return on equity of 0.00% beat biote's return on equity.Company Net Margins Return on Equity Return on Assets biote10.93% -19.44% 20.12% Connect Biopharma N/A N/A N/A Do institutionals and insiders have more ownership in BTMD or CNTB? 21.7% of biote shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 24.0% of biote shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Summarybiote beats Connect Biopharma on 6 of the 11 factors compared between the two stocks. Get Connect Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTB vs. The Competition Export to ExcelMetricConnect BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.10M$2.85B$5.42B$8.72BDividend YieldN/A2.69%5.37%4.21%P/E RatioN/A20.9825.0819.35Price / Sales2.03301.46405.37112.05Price / CashN/A43.0735.9456.46Price / Book0.577.337.995.50Net Income-$15.63M-$55.19M$3.14B$248.18M7 Day Performance-4.78%1.09%0.87%0.75%1 Month Performance26.13%8.30%5.14%4.44%1 Year Performance-28.40%0.64%38.93%16.85% Connect Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTBConnect Biopharma3.7054 of 5 stars$0.95-0.4%$7.00+635.1%-28.4%$53.10M$26.03M0.00110Positive NewsGap UpBTMDbiote3.1421 of 5 stars$3.98+5.3%$8.00+101.0%-42.7%$217.75M$199.38M15.31194Positive NewsINBXInhibrx1.8557 of 5 stars$14.62+0.3%N/A-1.2%$211.64M$200K0.13166News CoverageMNPRMonopar Therapeutics2.9845 of 5 stars$34.22+2.1%$55.33+61.7%+678.5%$209.26MN/A-17.3710Analyst ForecastSCPHscPharmaceuticals4.1625 of 5 stars$3.99+1.0%$14.00+250.9%+0.3%$208.53M$41.98M-2.1030GNFTGenfit2.6703 of 5 stars$4.13+0.8%$13.00+214.7%-0.4%$206.53M$67.00M0.00120Positive NewsIMABI-Mab2.3116 of 5 stars$2.52+1.2%$5.50+118.3%+61.6%$205.78M$3.27M0.00380CRGXCARGO Therapeutics1.6437 of 5 stars$4.42+0.7%$15.00+239.4%-72.2%$203.81MN/A-1.04116Positive NewsFDMT4D Molecular Therapeutics2.6946 of 5 stars$4.37-0.5%$29.56+576.3%-81.5%$202.44M$23K-1.53120PRQRProQR Therapeutics1.3346 of 5 stars$1.90+1.1%$8.00+321.1%+30.1%$199.91M$18.97M-5.94180Positive NewsDRUGBright Minds Biosciences2.6638 of 5 stars$28.24+2.4%$83.25+194.8%+2,322.9%$198.92MN/A-166.11N/ANews Coverage Related Companies and Tools Related Companies BTMD Competitors INBX Competitors MNPR Competitors SCPH Competitors GNFT Competitors IMAB Competitors CRGX Competitors FDMT Competitors PRQR Competitors DRUG Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTB) was last updated on 6/26/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTop Picks for Trump’s Pro-Crypto America27 of crypto's most successful minds are about to pull back the curtain… Bitcoin has crushed its all-time h...Crypto 101 Media | SponsoredWar Tensions Are Making Gold Rise to Record HighsIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
